de-ALARMIN
Financiado
Novel Prognostic Personalized Biomarker and Therapeutic Target in Blood Cancer...
Novel Prognostic Personalized Biomarker and Therapeutic Target in Blood Cancer Related Fibrosis
The objective of this ERC Proof of Concept is to demonstrate the clinical application and commercial viability of a specific driver of the innate immune system as a novel predictive biomarker and as a novel therapeutic target for...
The objective of this ERC Proof of Concept is to demonstrate the clinical application and commercial viability of a specific driver of the innate immune system as a novel predictive biomarker and as a novel therapeutic target for the diagnosis and treatment of bone marrow fibrosis related to blood cancer. This proposed project builds upon recent findings of my deFiber ERC Starting Grant (Stg) project, where we identified this danger-associated molecular pattern complex as exactly as such a prognostic and predictive biomarker and importantly showed that targeting with a small molecular, oral, anti-cancer inhibitor reduced fibrosis but also the cancer cell burden, in the sense of a targetable biomarker.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2021-04-23
Fecha Fin: 2023-04-30
Fecha Fin: 2023-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-04-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2020-POC:
Call for proposals for ERC Proof of Concept Grant
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDA...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.05M€ |
Participante